Photo taken from Yüksel Ürün/Twitter
Dec 2, 2023, 15:23
Yüksel Ürün: The ctDNA clearance during definitive SOC therapy is associated with improved outcome
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X/Twitter:
“A study shows combining circulating tumor DNA (ctDNA) analysis with radiological tumor volume can better predict relapse risk in early-stage non-small cell lung cancer (NSCLC).
Pre-operative or post-surgical ctDNA after definitive Standard of Care (SOC) treatments, are both predictive of relapse and overall survival in early-stage NSCLC. The ctDNA clearance during SOC therapy is associated with improved outcome.”
For more details, click here.
Source: Yüksel Ürün/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12
Dec 21, 2024, 13:05